Spots Global Cancer Trial Database for Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
Official Title: Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
Study ID: NCT01232881
Conditions
Study Description
Brief Summary: This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Detailed Description: OUTLINE: This is a multi-center study. Sample Collection: * Tumor sample * Serum sample Treatment Regimen: * All registered patients must be planning treatment with lonafarnib
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Contact Details
Name: George Sledge, M.D.
Affiliation: Hoosier Cancer Research Network
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
